The European Patent Office (EPO) has granted patent EP3365005B1, titled "Recombinant Mopeia Virus and Vaccine Platform." This patent, published on March 18, 2026, covers specific biotechnological inventions related to the development of vaccines using a recombinant Mopeia virus platform. The patent lists several inventors and includes IPC classifications related to vaccine preparation and genetic engineering.

This grant signifies the formal recognition of intellectual property rights for the patented technology. While this is a patent grant and not a regulatory rule imposing direct compliance obligations, it is relevant for companies operating in the vaccine and biotechnology sectors. Entities involved in similar research or seeking to utilize this technology should be aware of the granted patent and its scope, as it may impact their freedom to operate or necessitate licensing agreements.